Mitsubishi Materials Corporation

Astellas Pharma Gmbh

Tomohiko Yamaguchi

Masaaki Hirano

Tatsuya Niimi

Kazuhiko Yamasaki

Kiyotaka Nakaya

Takashi Furutani

Akio Kamikawa

Akio Kakefuda

Kentaro Enjo

Yutaka Kondoh

Kotaro Masuyama

Akihiro Higami

Kenichi Suzumura

Yasushi Amano

Koutarou Masuyama

Kohei Otogawa

Provided is a bonding sheet using a copper particle that is less prone to deteriorate the sintering property due to oxidation of the copper particle, and can form a dense bonding layer having fewer voids, and can also bond an electronic component and the like with a high bonding strength. A bonding sheet () contains a copper particle () and a solvent () having a boiling point of 150° C. or higher, in which the copper particle () has a surface covered with an organic protective film, the content ratio of the copper particle () to the solvent () is in the range of 99:1 to 90:10 by mass, and the BET diameter of the copper particle () is in the range of 50 nm to 300 nm both inclusive.

Bonding sheet

A metal particle aggregate includes metal particles and an organic substance. The metal particles include first particles that contain one or both of silver and copper in an amount of 70% by mass or more relative to 100% by mass of all metals and have a particle diameter of 100 nm or more and less than 500 nm at a ratio of 20 to 30% by number, and include second particles that have a particle diameter of 50 nm or more and less than 100 nm, and third particles that have a particle diameter of less than 50 nm at a ratio of 80 to 70% by number in total. Surfaces of the first to third particles are covered with the same protective film.

Metal particle aggregates, method for producing same, paste-like metal particle aggregate composition, and method for producing bonded body using said paste-like metal particle aggregate composition

To provide a novel and excellent method for treating and/or preventing prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, lung cancer, endometriosis, leiomyoma and the like based on selective inhibitory activity against 17&#x3b2;HSD type 5. It was found that an N-sulfonylindole derivative, where the indole ring is substituted by a carboxy group, a carboxy-substituted lower alkyl group or a carboxy-substituted lower alkenyl group at its carbon atom, has potent selective inhibitory activity against 17&#x3b2;HSD type 5 and may become a therapeutic agent and/or preventive agent for benign prostatic hyperplasia, prostatic cancer and the like without accompanying adverse drug reactions due to a decrease in testosterone, and the present invention has thus been completed.

17&#x3b2;HSD type 5 inhibitor

Growing community of inventors

Tokyo, Japan

Tomohiko Yamaguchi